Visoso PP, Izaguirre GVF

Language: Spanish
References: 32
Page: 84-90
PDF size: 223.73 Kb.

ABSTRACT

Introduction: Sepsis and septic shock are the main causes of admission to intensive care units, in the world it is estimated that 20-30 million cases of sepsis occur annually. One third or the half of these cases die.
Objective: The objective of this study was to evaluate the diagnostic efficiency of procalcitonin in sepsis and septic shock.
Material and methods: We perform an analytical, prospective, longitudinal observational study from September 1st, 2017 to May 31st, 2018, in the intensive care unit, procalcitonin as well as the classification of sepsis or septic shock criteria of SEPSIS-3 were taken at the time of admission, and the diagnostic efficiency of these biomarkers was performed.
Results: 171 patients were admitted to the ICU in this period, diagnosis of admission 63 (40.9%) admitted with sepsis, and of them 36 (57.1%) with septic shock, 91 (59.1%) with other diagnoses; It was APACHE II, quick-SOFA and SOFA 12.83 (± 7.92), 1.11 (± 0.92), 4.64 (± 3.03) in controls vs 22.45 (± 7.24), 2.14 (± 0.83), 8.18 (± 3.50) in patients with Sepsis or septic shock, the three p ‹ 0.001. The determination of procalcitonin in controls vs patients with sepsis / septic shock was: 2.37 ± 5.88 vs 13.22 ± 15.84 with p value of ‹ 0.001. The efficacy of procalcitonin for diagnosing sepsis (sepsis criteria 3), sensitivity 60%, specificity 75.4%, positive predictive value 68.8%, negative predictive value 67.6% and the area under the curve of the operative characteristic of the receiver was 0.767.
Conclusion: In conclusion, procalcitonin on admission to the intensive care unit serves as a biomarker for the diagnosis of sepsis/septic shock, however it should not be used as a single test, always in conjunction with the diagnostic criteria.

REFERENCES

1. Geroulanos S, Douka ET. Historical perspective of the word “sepsis”. Intensive Care Med. 2006;32(12):2077.

2. Funk DJ, Parrillo JE, Kumar A. Sepsis and septic shock: a history. Crit Care Clin. 2009;25(1):83-101, viii.

3. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20(6):864-874.

4. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 2003;29(4):530-538.

5. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29(7):1303-1310.

6. Engel C, Brunkhorst FM, Bone HG, Brunkhorst R, Gerlach H, Grond S, et al. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med. 2007;33(4):606-618.

7. International Organizations Declare Sepsis a Medical Emergency. Issued by an expert panel Representing 20 adult and pediatric intensive care societies, October 4th 2010. 2010: Press release. [Ingresado el 17 mayo de 2017] Available in: http://www.prnewswire.com/news-releases/international-organizations-declaresepsis-a-global-medical-emergency-104142073.html.

8. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323-2329.

9. Machado FR, Cavalcanti AB, Bozza FA, Ferreira EM, Angotti Carrara FS, Sousa JL, et al. The epidemiology of sepsis in Brazilian intensive care units (the Sepsis PREvalence Assessment Database, SPREAD): an observational study. Lancet Infect Dis. 2017;17(11):1180-1189.

10. Sogayar AM, Machado FR, Rea-Neto A, Dornas A, Grion CM, Lobo SM, et al. A multicentre, prospective study to evaluate costs of septic patients in Brazilian intensive care units. Pharmacoeconomics. 2008;26(5):425-434.

11. Prevention Epicenter Program. Incidence and Trends of Sepsis in US Hospitals Using Clinical vs Claims Data, 2009-2014. JAMA. 2017;318(13):1241-1249.

12. Burchardi H, Schneider H. Economic aspects of severe sepsis: a review of intensive care unit costs, cost of illness and cost effectiveness of therapy. Pharmacoeconomics. 2004;22(12):793-813.

13. Carrillo-Esper R, Carrillo-Córdova JR, Carrillo-Córdova LD. Estudio epidemiológico de la sepsis en unidades de terapia intensiva mexicanas. Cir Cir. 2009;77(4):301-308.

14. Ponce de León-Rosales SP, Molinar-Ramos F, Domínguez-Cherit G, Rangel-Frausto MS, Vázquez-Ramos VG. Prevalence of infections in intensive care units in Mexico: a multicenter study. Crit Care Med. 2000;28(5):1316-1321.

15. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315(8):801-810.

16. Nargis W, Ibrahim M, Ahamed BU. Procalcitonin versus C-reactive protein: Usefulness as biomarker of sepsis in ICU patient. Int J Crit Illn Inj Sci. 2014;4(3):195-199.

17. Joen JS, Ji SM. Diagnostic value of procalcitonin and CRP in critically ill patients admitted with suspected sepsis. J Dent Anesth Pain Med. 2015;15(3):135-140.

18. Castelli GP, Pognani C, Meisner M, Stuani A, Bellomi D, Sgarbi L. Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction. Crit Care. 2004;8(4):R234-R242.

19. Chan T, Gu F. Early diagnosis of sepsis using serum biomarkers. Expert Rev Mol Diagn. 2011;11(5):487-496.

20. Seligman R, Meisner M, Lisboa TC, Hertz FT, Filippin TB, Fachel JM, et al. Decreases in procalcitonin and C-reactive protein are strong predictors of survival in ventilator-associated pneumonia. Crit Care. 2006;10(5):R125.

21. Vincent JL, Opal SM, Marshall JC, Tracey KJ. Sepsis definitions: time for change. Lancet. 2013;381(9868):774-775.

22. Marshall JC, Reinhart K; International Sepsis Forum. Biomarkers of sepsis. Crit Care Med. 2009;37(7):2290-2298.

23. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care. 2010;14(1):R15.

24. Choi JJ, McCarthy MW. Novel applications for serum procalcitonin testing in clinical practice. Expert Rev Mol Diagn. 2018;18(1):27-34.

25. Fazili T, Endy T, Javaid W, Maskey M. Role of procalcitonin in guiding antibiotic therapy. Am J Health Syst Pharm. 2012;69(23):2057-2061.

26. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, et al. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010;375(9713):463-474.

27. Hochreiter M, Köhler T, Schweiger AM, Keck FS, Bein B, von Spiegel T, et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care. 2009;13(3):R83.

28. Michaelidis C, Zimmerman RK, Nowalk MP, Fine MJ, Smith KJ. Cost-effectiveness of procalcitonin-guided antibiotic therapy for outpatient management of acute respiratory tract infections in adults. J Gen Intern Med. 2014;29(4):579-586.

29. Ljungström L, Pernestig AK, Jacobsson G, Andersson R, Usener B, Tilevik D. Diagnostic accuracy of procalcitonin, neutrophil-lymphocyte count ratio, C-reactive protein, and lactate in patients with suspected bacterial sepsis. PLoS One. 2017;12(7):e0181704.

30. Lin CT, Lu JJ, Chen YC, Kok VC, Horng JT. Diagnostic value of serum procalcitonin, lactate, and high-sensitivity C-reactive protein for predicting bacteremia in adult patients in the emergency department. PeerJ. 2017;5:e4094.

31. Wu CC, Lan HM, Han ST, Chaou CH, Yeh CF, Liu SH, et al. Comparison of diagnostic accuracy in sepsis between presepsin, procalcitonin, and C-reactive protein: a systematic review and meta-analysis. Ann Intensive Care. 2017;7(1):91.

32. Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(5):426-435.